Balance Sheet: Assets
Quarterly Data
The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.
Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Regeneron Pharmaceuticals Inc., consolidated balance sheet: assets (quarterly data)
US$ in thousands
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
Total assets exhibited a consistent and substantial growth trajectory, increasing from $17.77 billion in March 2021 to $40.87 billion by March 2026. This expansion was driven by simultaneous increases in both current and noncurrent asset categories, reflecting a significant broadening of the organization's financial base over the five-year period.
- Liquidity and Current Asset Trends
- Current assets rose from $10.06 billion to $18.21 billion. While cash and cash equivalents demonstrated periodic volatility—peaking at $3.92 billion in March 2023 before stabilizing around $2.96 billion—the overall liquid position was strengthened by current marketable securities, which grew from $2.07 billion to $5.79 billion. Accounts receivable, net, and inventories also showed steady upward trends, increasing to $5.73 billion and $3.10 billion respectively, suggesting an expansion in operational scale and sales activity.
- Noncurrent Asset Expansion
- Noncurrent assets experienced more aggressive growth than current assets, moving from $7.72 billion to $22.66 billion. A primary contributor to this increase was noncurrent marketable securities, which surged from $3.54 billion to $9.79 billion. Additionally, property, plant, and equipment (net) followed a linear growth path, rising from $3.26 billion to $5.27 billion, indicating sustained investment in physical infrastructure and production capabilities.
- Intangible and Deferred Asset Growth
- Intangible assets, which first appeared in the reporting in September 2022 at $804.1 million, grew to $1.29 billion by March 2026. A notable trend is observed in deferred tax assets, which saw a sharp escalation from $765.1 million to $4.19 billion. Similarly, other noncurrent assets increased significantly from $145.7 million to $2.13 billion, contributing to the overall inflation of the noncurrent asset base.